GLP‑1s and PCOS: what the research shows

Are GLP-1 medicines approved for PCOS?

No. None of the GLP-1 medicines has PCOS on its label. When a clinician prescribes Wegovy or Zepbound to someone with PCOS, it is for weight management, in adults with obesity or with overweight and at least one weight-related condition, which is what those labels cover. Ozempic and Mounjaro are approved for type 2 diabetes, which is more common in PCOS.

Medical guidance does include them. The 2023 International Evidence-based Guideline for PCOS, written by an international network of experts and women with PCOS, says anti-obesity medicines including liraglutide and semaglutide could be considered, in addition to active lifestyle changes, for managing higher weight in adults with PCOS, following general population guidelines. It also asks clinicians to talk through side effects and the likely need for long-term use, since weight often returns after stopping.

What does the research on GLP-1s and PCOS show?

The trials consistently show less weight and a smaller waist, but they are small and short, and most used liraglutide, an older daily GLP-1. Very little has been published on semaglutide in PCOS and we could not find a published randomized trial of tirzepatide in PCOS.

Every one of these reviews says the same thing in the end: the results are encouraging for weight, and better trials are needed for everything else, including periods, ovulation, fertility, acne and hair growth. If someone tells you a GLP-1 will fix your cycle or your skin, that goes beyond what the studies have shown.

How does insulin resistance fit in?

Insulin resistance is common in PCOS, and the guideline says women with PCOS have a higher risk of prediabetes and type 2 diabetes regardless of their weight. It recommends checking blood sugar status at diagnosis and every 1 to 3 years after that, ideally with an oral glucose tolerance test, and again when planning pregnancy.

GLP-1 medicines help the body release insulin when blood sugar rises and slow how fast food leaves the stomach. In PCOS trials, the picture on insulin resistance is mixed: GLP-1 medicines beat metformin on insulin sensitivity in one review, but did not significantly beat placebo on HOMA-IR in another. The guideline still says metformin should be considered for the metabolic side of PCOS, including insulin resistance, in adults with a BMI of 25 or more.

Food still matters. Building meals around protein, fiber-rich vegetables, beans and whole grains supports steadier blood sugar and helps you feel full on less. Our guide on what to eat has simple ideas. The 2025–2030 Dietary Guidelines suggest 1.2 to 1.6 g of protein per kg a day; the protein calculator gives your number.

What do the labels say about pregnancy?

The weight-management labels say to stop when pregnancy is recognized, and the semaglutide labels add a stopping window before a planned pregnancy. Animal studies showed possible harm to the fetus, and there is not enough human data to know the risk. The diabetes labels leave use in pregnancy to a benefit-and-risk decision, because poorly controlled diabetes in pregnancy also carries risks.

The Zepbound label does not give a fixed number of weeks to stop before trying to conceive. If you are planning a pregnancy on any GLP-1, follow your prescriber and the label on when to stop, and plan it at a visit before you start trying. That visit is also a good time for the glucose test the PCOS guideline recommends.

Irregular periods do not mean you cannot get pregnant. If pregnancy is possible and you do not want it, use reliable contraception, as the guideline advises. If you find out you are pregnant while on a GLP-1, contact your prescriber promptly. Each medicine has a pregnancy registry listed on its label.

Do GLP-1s affect birth control pills?

Tirzepatide does, according to its labels. The Zepbound and Mounjaro labels say tirzepatide may make oral hormonal contraceptives less effective because it slows stomach emptying, an effect that is largest after the first dose and fades over time.

The labels advise people on the pill to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Contraceptives that are not taken by mouth, such as an IUD, implant, patch, ring or shot, should not be affected.

The Wegovy and Ozempic labels do not carry this advice. Many women with PCOS take a combined pill to manage cycles or skin, so if you take one and start tirzepatide, ask your prescriber how the label guidance applies to you before your first shot.

What should you ask your clinician?

A short list makes the visit easier:

• Is a GLP-1 a good fit for my PCOS, and what are we hoping it changes?
• Should I have a glucose tolerance test or other labs first?
• Which birth control works best with this medicine?
• If I want to get pregnant in the next year or two, when should I stop, and what happens to my PCOS care then?
• How will we check my progress beyond weight: cycles, labs, blood pressure?

Contact your clinician or seek care if you have severe stomach pain that will not go away, pain that spreads to your back, vomiting you cannot keep fluids down through, signs of dehydration, a lump in your neck, or signs of an allergic reaction.

Questions

Keep reading

Educational information, not medical advice. Talk to your clinician about your treatment.